Based on this and the known upregulation of E-selectin observed on BM vessels adjacent to the leukemic cell [9, 11–13], we have developed a novel approach to efficiently redirect NK cells to the AML niche, which may be explored to improve response rates of adoptive NK cell immunotherapy against myeloid leukemia. The gene discussed is SELE; the disease is acute myeloid leukemia.